This Core serves two functions. The first is to provide a service to other TCORS investigators by carrying out the analysis of biofluid samples for their studies. The second is to develop new biomarkers of exposure that can be applied to the studies carried out by TCORS investigators, as well as to advance the field. Our laboratory is able to measure alkaloids and toxic substances in both tobacco products and in tobacco smoke. These measurements are needed for biomarker development and to interpret the biomarker data for distinguishing smokeless from smoked tobacco use. These measurements will include other substances in order to explore relationships between toxins and toxin precursors in tobacco and smoke with exposure determined using biomarkers. The improved exposure assessment measures that we expect to develop, and their application to studies carried out by the TCORS, could serve as models for future studies of the risks of new tobacco products and provide scientific basis for their regulation.

Public Health Relevance

The development and validation of biomarkers is a high priority issue for FDA regulation. Studies of tobacco product chemistry with biomarker analyses may provide information on which substances are associated with toxin exposure in humans. Precursors in smoking products that generate toxic substances might provide leads for reducing the toxicity of new products or be targets for regulation. We expect that our studies will result in improved methods for determining human exposure to toxic substances in tobacco and tobacco smoke.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-BDCN-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Max, Wendy B; Sung, Hai-Yen; Lightwood, James et al. (2018) Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product. Tob Control 27:s82-s86
Sung, Hai-Yen; Wang, Yingning; Yao, Tingting et al. (2018) Polytobacco Use and Nicotine Dependence Symptoms Among US Adults, 2012-2014. Nicotine Tob Res 20:S88-S98
Cheng, Jing; Lin, Winston (2018) Understanding Causal Distributional and Subgroup Effects With the Instrumental Propensity Score. Am J Epidemiol 187:614-622
Chaffee, Benjamin W; Couch, Elizabeth T; Gansky, Stuart A (2018) Adolescents' smokeless tobacco susceptibility by perceived professional baseball players' use. J Public Health Dent 78:5-8
McKelvey, Karma; Popova, Lucy; Kim, Minji et al. (2018) Heated tobacco products likely appeal to adolescents and young adults. Tob Control 27:s41-s47
McKelvey, Karma; Popova, Lucy; Pepper, Jessica K et al. (2018) Adolescents have unfavorable opinions of adolescents who use e-cigarettes. PLoS One 13:e0206352
Chun, Lauren; Moazed, Farzad; Matthay, Michael et al. (2018) Possible hepatotoxicity of IQOS. Tob Control 27:s39-s40
Morean, Meghan E; Krishnan-Sarin, Suchitra; Sussman, Steve et al. (2018) Development and psychometric validation of a novel measure of sensory expectancies associated with E-cigarette use. Addict Behav :
Vogel, Erin A; Ramo, Danielle E; Rubinstein, Mark L (2018) Prevalence and correlates of adolescents' e-cigarette use frequency and dependence. Drug Alcohol Depend 188:109-112
Rubinstein, Mark L; Delucchi, Kevin; Benowitz, Neal L et al. (2018) Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes. Pediatrics 141:

Showing the most recent 10 out of 101 publications